Quoin Pharmaceuticals Ltd. (QNRX): Shareholders' Equity
$13.12M
As of 2025-12-31
$3.93M
As of 2026-06-30
+21.0%
3-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $13.12M | +42.5% | 2026-03-26, Balance as of period end |
| 2024-12-31 | $9.20M | +62.5% | 2026-03-26, Balance as of period end |
| 2023-12-31 | $5.66M | -23.5% | 2025-03-13, Balance as of period end |
| 2022-12-31 | $7.41M | n/m | 2024-03-14, Balance as of period end |
| 2021-12-31 | $657.0K | n/m | 2023-03-15, Balance as of period end |
| 2020-12-31 | -$6.61M | n/m | 2022-04-14, Balance as of period end |
| 2019-12-31 | -$4.51M | n/a | 2022-04-14, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | 2025-12-31 | $13.12M | +42.5% |
| Nexentis Technologies Inc. (NXTS) | 2025-12-31 | $16.01M | +237.1% |
| Evofem Biosciences, Inc. (EVFM) | 2025-12-31 | -$74.34M | n/m |
| Jyong Biotech Ltd. (MENS) | 2025-12-31 | -$24.91M | n/m |
| Abvc Biopharma, Inc. (ABVC) | 2025-12-31 | $11.11M | +806.2% |
| Annovis Bio, Inc. (ANVS) | 2025-12-31 | $16.85M | +81.0% |
| Galectin Therapeutics Inc (GALT) | 2025-12-31 | -$127.92M | n/m |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | -$63.61M | n/m |
| Phio Pharmaceuticals Corp. (PHIO) | 2025-12-31 | $20.15M | +326.6% |
Compare QNRX, NXTS, EVFM, MENS side by side · Screen every company in Pharmaceutical Preparations ↗